Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 420,000 | 140.7% |
| Gross Profit | -17M | 61.8% |
| Cost of Revenue | 18M | 59.9% |
| Operating expense | 39M | 42.4% |
| Net Income | -73M | 0% |
| EBITDA | -76M | 42.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 251M | 24.5% |
| Total Liabilities | 55M | 23.1% |
| Total Equity | 196M | 24.9% |
| Shares Outstanding | 69M | 0.7% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -42M | 37.6% |
| Cash from investing | 39M | 234% |
| Cash from financing | 80,000 | 196.3% |
EPS
Financial Highlights for Amylyx Pharmaceuticals in Q3 '24
Amylyx Pharmaceuticals reported a revenue of 420,000, which is a 140.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -17M, marking a 61.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 18M, a -59.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 39M, showing a -42.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -73M, showing a -0% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -76M, showing a -42.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Amylyx Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
